|
|
Post by pmikeks on Jul 27, 2015 19:21:05 GMT -5
I have been on Affrezza three months. When I started my A1c was 9.2 and I fully expect it to be under 6.0 when I have my follow up this week. I was taking 30 units of Lantus nightly when I started and granted I wasn't behaving as I should. But now when I do splurge (example; pizza and homemade ice cream) my peak isn't as high and doesn't last as long.
Many days at bedtime my blood sugar is under 100 so I don't take Lantus and my fasting blood sugar is still under 100 come morning. Other days because my count is under 130 I take a lesser amount of Lantus (15-25 units). Sooo.as a result I'm using less then a third of the Lantus I was taking to start with. It's like my pancreas has decided to jump in and help. It didn't happen immediately or even with consistent improvement
Are my results after three months typical? I don't have the answer to that. If they are typical it may be part of why SNY isn't as enthusiastic as we would like them to be in promoting Affrezza.
|
|
|
|
Post by mannmade on Jul 27, 2015 19:27:36 GMT -5
I have been on Affrezza three months. When I started my A1c was 9.2 and I fully expect it to be under 6.0 when I have my follow up this week. I was taking 30 units of Lantus nightly when I started and granted I wasn't behaving as I should. But now when I do splurge (example; pizza and homemade ice cream) my peak isn't as high and doesn't last as long. Many days at bedtime my blood sugar is under 100 so I don't take Lantus and my fasting blood sugar is still under 100 come morning. Other days because my count is under 130 I take a lesser amount of Lantus (15-25 units). Sooo.as a result I'm using less then a third of the Lantus I was taking to start with. It's like my pancreas has decided to jump in and help. It didn't happen immediately or even with consistent improvement Are my results after three months typical? I don't have the answer to that. If they are typical it may be part of why SNY isn't as enthusiastic as we would like them to be in promoting Affrezza. pmikeks, I am neither a doctor nor a diabetic but my understanding from reading posts from people who are both, suggests your results are very much in line with the vast majority of other diabetics on Afrezza. Namely they see the reversal of insulin resistance requiring lower basal doses and the elimination/disappearance of the "dawn effect." In effect Afrezza restores the normal communication between the pancreas and the liver and your body acts as if it were normal (non-diabetic). Take a read of Compounds article that he drafted of SA under the thread for Articles and Media. You will find many other benefits from Afrezza that users are experiencing. Continued good health to you... |
|
|
|
Post by dreamboatcruise on Jul 27, 2015 19:38:25 GMT -5
pmikeks... do you know if your endo is prescribing to other patients? We're you on another prandial or is Afrezza your first?
|
|
|
|
Post by pmikeks on Jul 27, 2015 20:09:24 GMT -5
pmikeks... do you know if your endo is prescribing to other patients? We're you on another prandial or is Afrezza your first? No I wasn't on another prandial and I went about 8 years before they got me to stick a needle in myself. I go to a GP who I had to make give me a prescription for Affrezza he wanted to put me on Farxiga. While he claimed to know about Affrezza his dosage instructions was not to take it if my BS was under 120 to avoid hypos, I told him he needed to do some DD on it. I can't wait to discuss results with him.  |
|
|
|
Post by kc on Jul 27, 2015 20:19:36 GMT -5
Wow! congratulations on the success you have been having on Afrezza. based on your limited information, I can see why Big Pharma including Sanofi might be disturbed about the implication of the product working so well. This could really be devastating for the entire Pharma industry if this easy to use product was actually as good as the results you and others have been having.
Pancreas working better. Taking less injections. Oh my.
You can see why every body is gunning for killing MannKind.
"Many days at bedtime my blood sugar is under 100 so I don't take Lantus and my fasting blood sugar is still under 100 come morning. Other days because my count is under 130 I take a lesser amount of Lantus (15-25 units). Sooo.as a result I'm using less then a third of the Lantus I was taking to start with. It's like my pancreas has decided to jump in and help. It didn't happen immediately or even with consistent improvement "
|
|
|
|
Post by dreamboatcruise on Jul 27, 2015 20:32:06 GMT -5
pmikeks... do you know if your endo is prescribing to other patients? We're you on another prandial or is Afrezza your first? No I wasn't on another prandial and I went about 8 years before they got me to stick a needle in myself. I go to a GP who I had to make give me a prescription for Affrezza he wanted to put me on Farxiga. While he claimed to know about Affrezza his dosage instructions was not to take it if my BS was under 120 to avoid hypos, I told him he needed to do some DD on it. I can't wait to discuss results with him. Would love to get a follow up to hear his reaction. Do you get labs done before the visit so he has them for the appointment? I have been impressed with SNY getting Toujeo on preferred status on about a quarter of insured patients, but I still think with it going off patent and with pricing pressure they don't really stand to lose a heck of a lot, if any, from 65% stake in Afrezza even if there is some cannibalization of basal market. As for the rest of the BP players in diabetes, they undoubtedly are hoping Afrezza does poorly. |
|
|
|
Post by pmikeks on Jul 27, 2015 20:53:38 GMT -5
Dreamboatcruise- Your post __Would love to get a follow up to hear his reaction. Do you get labs done before the visit so he has them for the appointment? Yes labs are done before the visit because I'll make sure it is.  I'll follow up after I meet with him...it may be next week before I make appointment he only works Mon-Thur. |
|
|
|
Post by ishorr on Jul 27, 2015 21:39:42 GMT -5
Thanks for the "real world" feedback. I'm wondering what others think about your point-- that SNY might be holding back because Afrezza negatively impacts Lantus sales. Does this mean they didn't know what they were partnering with?
|
|
|
|
Post by babaoriley on Jul 27, 2015 22:09:04 GMT -5
Thanks for the "real world" feedback. I'm wondering what others think about your point-- that SNY might be holding back because Afrezza negatively impacts Lantus sales. Does this mean they didn't know what they were partnering with? Al had made such a claim on several occasions, so I'm sure they knew all about it. Here's the deal, if you're SNY and your investigation tells you that Al could be right, you damn well sure don't want Lilly or Novo getting their hands on it, because if they do, it can hurt SNY. This way, SNY is not hurt, benefits a lot, although not 100% due to the lower usage of Toujeo, but they can stick it to Lilly and Novo. Thanks for all the info pmikeks, keep up the great work and results; we will be on the edge of our seats waiting for your new A1c number!! By the way, you know it actually takes 120 days to get the most reliable number for your new A1c, but I'm confident by your description that we're all gonna love your number! |
|
|
|
Post by mannmade on Jul 27, 2015 22:51:43 GMT -5
Thanks for the "real world" feedback. I'm wondering what others think about your point-- that SNY might be holding back because Afrezza negatively impacts Lantus sales. Does this mean they didn't know what they were partnering with? I would have to agree w Baba and say for Sanofi it would be just the opposite. That is so what if it hurts Lantus/Toujeo not to mention Novolog and Humalog as that would mean they could dominate diabetes at least for insulin. Remember mnkd has very tight and long patent protection. To me if I were Sanofi I would be thrilled if Afrezza were to cannobalize basal sales as that means more growth from customers of the competition. And the competition would have no answer for Afrezza w which to compete. |
|
|
|
Post by mnholdem on Jul 28, 2015 7:03:04 GMT -5
You guys are talking about domination of the market for Type 1 diabetics, who require daily basal injections (albeit allegedly less units while using Afrezza) and who account for roughly 10% of the diabetes treatment market.
The motherlode that Sanofi is really preparing to dig for is to have Afrezza insulin therapy replace Medformin as the standard first treatment for pre- and early-diabetics. Remember, Medformin doesn't "fix" anything nor keep the pancreas from deteriorating. Afrezza, on the other hand, has been shown to have remarkable "regenerative" effects on the pancreas and liver.
I wouldn't worry about Sanofi executives fretting over the impact on Lantus, when there is a whole world of Type 2 treatment with the potential to generate many times the revenue that Lantus/Toujeo account for.
Some pharmaceutical executives may frown on the idea of "remission" since it means that, unlike Type 1's, many early Type 2 patients may only need to receive intensive therapy for a relatively short period of time using Afrezza. Then, when the pancreas has "rested" and their bodies' control of blood glucose appears to be functioning normally again, they need only maintain a regimen of diet and exercise.
Stop and think about the PR benefits to a pharmaceutical company for a drug like that. Medformin cannot make that claim, nor any analog insulin, GLP-1's or the latest and greatest within the "alphabet soup" of diabetes treatments.
Afrezza is the only one which will have the ability to boast that it may be effectively used initially as a short-term treatment to stop the deterioration of the pancreas and, in essence, to stop the progression and possibly even remission of this destructive disease at its onset.
Afrezza truly represents a paradigm shift in the treatment of diabetes that can and will add years to the lives of millions, lives that can be lived normally. It's a fact not being overlooked by Sanofi and it should NOT be overlooked by long-term investors in MNKD.
|
|
|
|
Post by cusop on Jul 28, 2015 7:38:02 GMT -5
These results are scary, if one considers that Insulin resistance is function of the body fighting the over supply of insulin during the day, the fact that inhaled insulin reverses this effect is quite amazing. But also it means that Sanofi have a dilemma and that is, one it already has the world wide rights to Afrezza, and it could dominate the market. The key to avoiding to cannibalising its own market is for it to
1. To use its own insulin
2. Report these effects when the combination uses there own insulin,
Would am mojor corporation do something like that !!?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 28, 2015 7:51:34 GMT -5
These results are scary, if one considers that Insulin resistance is function of the body fighting the over supply of insulin during the day, the fact that inhaled insulin reverses this effect is quite amazing. But also it means that Sanofi have a dilemma and that is, one it already has the world wide rights to Afrezza, and it could dominate the market. The key to avoiding to cannibalising its own market is for it to 1. To use its own insulin 2. Report these effects when the combination uses there own insulin, Would am mojor corporation do something like that !!? SNY may have to eat some of their young if it means putting together a combo price of Afrezza & Toujeo and taking share of Prandial and Basal from the other two players. Also to MN's point, the type 2 market is huge. Hopefully in the next month or so we start to see a nice growth trend week to week of NRx and TRx. More patients = financial viability of Afrezza for SNY and MNKD. With a consolidation of the health insurers, they can see their claims data and mine it to determine how Afrezza impacts A1C, frequency of physician visits and in time, reduction of health complications and associated costs of treating them. Hopefully I'm typeone will communicate to her health insurer how Afrezza stopped the progression of her diabetes and ended the need for further laser treatments as her retinopathy stopped progressing. I don't want to sound heartless but what the health insurance companies may quickly come to understand is that Afrezza not only improves the health and quality of life for the patient, but saves the insurer a boatload of money. |
|
|
|
Post by mssciguy on Jul 28, 2015 8:27:56 GMT -5
mnholdem, I reposted that to ymb (with attribution). Someone named target3 gave the following reply:
"Be very cautious bout blanket statements regarding type 2 diabetics. There are various reasons not all understood, some are not reversible, others take diet and exercise"
|
|
|
|
Post by mnholdem on Jul 28, 2015 10:45:10 GMT -5
As these discussion boards are investment related, I tend to speak in broader terms. As any doc will tell you, there are always medical exceptions, and Afrezza may benefit some Type 2's much better than others. That said, my point was that the Type 2 market is huge, as is the potential for Afrezza to successfully treat millions of patients within that market. That factor should more than offset any impact Afrezza may have on Sanofi due to any reduction in Lantus dosages by Afrezza users.
Thanks for passing along the comment.
|
|
I'll follow up after I meet with him...it may be next week before I make appointment he only works Mon-Thur. 
